These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 34799964)

  • 41. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
    Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
    Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.
    Veit T; Munker D; Kauke T; Zoller M; Michel S; Ceelen F; Schiopu S; Barton J; Arnold P; Milger K; Behr J; Kneidinger N
    Transplantation; 2020 Feb; 104(2):410-414. PubMed ID: 31385924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
    Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
    Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.
    Snyder LD; Medinas R; Chan C; Sparks S; Davis WA; Palmer SM; Weinhold KJ
    Am J Transplant; 2011 Mar; 11(3):553-60. PubMed ID: 21219584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences.
    Hirama T; Shundo Y; Watanabe T; Ohsumi A; Watanabe T; Okada Y
    Clin Exp Med; 2024 Apr; 24(1):68. PubMed ID: 38578337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
    Fukuda M; Hattori J; Ohkubo R; Watanabe A; Maekawa S
    Clin Drug Investig; 2024 Jul; 44(7):527-540. PubMed ID: 38935253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients.
    Linder KA; Kovacs C; Mullane KM; Wolfe C; Clark NM; La Hoz RM; Smith J; Kotton CN; Limaye AP; Malinis M; Hakki M; Mishkin A; Gonzalez AA; Prono MD; Ostrander D; Avery R; Kaul DR
    Transpl Infect Dis; 2021 Aug; 23(4):e13687. PubMed ID: 34251742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
    Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
    Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An overview of letermovir: a cytomegalovirus prophylactic option.
    Gerna G; Lilleri D; Baldanti F
    Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
    [No Abstract]   [Full Text] [Related]  

  • 54. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
    Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
    Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
    Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
    Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
    Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
    Am J Transplant; 2010 Jan; 10(1):157-61. PubMed ID: 19889123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high-risk abdominal transplant recipients.
    Kreiser ML; Dupuis R; Szempruch KR; Chargualaf LM
    Clin Transplant; 2023 Oct; 37(10):e15041. PubMed ID: 37256906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence and risk factors for the development of cytomegalovirus viremia in a steroid sparing liver transplant center.
    Viehl E; Lichvar A; Chan C; Choi D
    Transpl Infect Dis; 2022 Aug; 24(4):e13867. PubMed ID: 35604549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.